CA2305289A1 - Utilisation de thiazolidinediones pour le traitement de l'hyperglycemie - Google Patents

Utilisation de thiazolidinediones pour le traitement de l'hyperglycemie Download PDF

Info

Publication number
CA2305289A1
CA2305289A1 CA002305289A CA2305289A CA2305289A1 CA 2305289 A1 CA2305289 A1 CA 2305289A1 CA 002305289 A CA002305289 A CA 002305289A CA 2305289 A CA2305289 A CA 2305289A CA 2305289 A1 CA2305289 A1 CA 2305289A1
Authority
CA
Canada
Prior art keywords
hyperglycaemia
glucose levels
plasma glucose
range
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002305289A
Other languages
English (en)
Inventor
Robin Edwin Buckingham
Stephen Alistair Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2305289A1 publication Critical patent/CA2305289A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Procédé de traitement de l'hyperglycémie pour laquelle le taux plasmique de glucose se situe entre ?126 mg/dl et 140 mg/dl. Ledit procédé consiste à administrer à un mammifère qui le nécessite une quantité efficace, non toxique et acceptable sur le plan pharmaceutique d'un sensibilisant à l'insuline.
CA002305289A 1997-10-13 1998-10-12 Utilisation de thiazolidinediones pour le traitement de l'hyperglycemie Abandoned CA2305289A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9721692.3A GB9721692D0 (en) 1997-10-13 1997-10-13 Novel treatment
GB9721692.3 1997-10-13
PCT/GB1998/003067 WO1999018944A1 (fr) 1997-10-13 1998-10-12 Utilisation de thiazolidinediones pour le traitement de l'hyperglycemie

Publications (1)

Publication Number Publication Date
CA2305289A1 true CA2305289A1 (fr) 1999-04-22

Family

ID=10820481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002305289A Abandoned CA2305289A1 (fr) 1997-10-13 1998-10-12 Utilisation de thiazolidinediones pour le traitement de l'hyperglycemie

Country Status (24)

Country Link
EP (1) EP1023057A1 (fr)
JP (1) JP2001519383A (fr)
KR (1) KR20010024482A (fr)
CN (1) CN1281358A (fr)
AP (1) AP1223A (fr)
AU (1) AU9547198A (fr)
BG (1) BG104405A (fr)
BR (1) BR9815220A (fr)
CA (1) CA2305289A1 (fr)
CZ (1) CZ20001298A3 (fr)
EA (1) EA200000418A1 (fr)
GB (1) GB9721692D0 (fr)
HR (1) HRP20000256A2 (fr)
HU (1) HUP0003673A3 (fr)
ID (1) ID24439A (fr)
IL (1) IL135515A0 (fr)
NO (1) NO20001897L (fr)
OA (1) OA11519A (fr)
PL (1) PL339804A1 (fr)
SK (1) SK5322000A3 (fr)
TR (1) TR200000957T2 (fr)
UA (1) UA66809C2 (fr)
WO (1) WO1999018944A1 (fr)
YU (1) YU28700A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2001002036A0 (en) * 1998-07-21 2001-03-31 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing apoptosis.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (fr) * 1987-09-04 1998-05-20 Beecham Group Plc Thiazolidinédiones substituées
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus

Also Published As

Publication number Publication date
CN1281358A (zh) 2001-01-24
YU28700A (sh) 2003-10-31
CZ20001298A3 (cs) 2001-08-15
IL135515A0 (en) 2001-05-20
SK5322000A3 (en) 2000-09-12
AP2000001788A0 (en) 2000-06-30
HRP20000256A2 (en) 2000-12-31
TR200000957T2 (tr) 2000-08-21
PL339804A1 (en) 2001-01-02
EA200000418A1 (ru) 2000-10-30
AU9547198A (en) 1999-05-03
NO20001897L (no) 2000-06-09
KR20010024482A (ko) 2001-03-26
WO1999018944A1 (fr) 1999-04-22
HUP0003673A3 (en) 2001-12-28
AP1223A (en) 2003-11-13
ID24439A (id) 2000-07-20
BG104405A (en) 2000-12-29
HUP0003673A2 (hu) 2001-10-28
NO20001897D0 (no) 2000-04-12
UA66809C2 (uk) 2004-06-15
JP2001519383A (ja) 2001-10-23
BR9815220A (pt) 2000-11-14
GB9721692D0 (en) 1997-12-10
EP1023057A1 (fr) 2000-08-02
OA11519A (en) 2004-02-09

Similar Documents

Publication Publication Date Title
AU8539398A (en) Treatment of diabetes with thiazolidinedione and metformin
AU8448898A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
CA2297115C (fr) Traitement du diabete avec du thiazolidinedione et de la sulfonyluree
AU8449098A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
CA2294134A1 (fr) Traitement du diabete a l'aide de thiazolidinedione et d'un inhibiteur des alpha-glucosidases
US20020137773A1 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
US20030069283A1 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
CA2305289A1 (fr) Utilisation de thiazolidinediones pour le traitement de l'hyperglycemie
CA2306086A1 (fr) Utilisation de thiazolidinediones pour le traitement de l'hyperglycemie
AU4586902A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
AU4587002A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
MXPA00003633A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
MXPA00003634A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
US20010034356A1 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
CA2549864A1 (fr) Traitement du diabete a l'aide de thiazolidinedione et de metformine
AU1011902A (en) Treatment of diabetes with thiazolidinedione and metformin
MXPA99012098A (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued